NPX 267
Alternative Names: NPX-267Latest Information Update: 15 Sep 2023
At a glance
- Originator NextPoint Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; KIR3DL3 protein antagonists; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Aug 2023 Phase-I clinical trials in Solid tumours (Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT05958199)
- 31 Jul 2023 NextPoint Therapeutics plans a phase Ia/Ib trial for Solid tumours (Recurrent, Metastatic disease, Second-line therapy or greater) in USA (IV), in July 2023(NCT05958199)
- 07 Nov 2022 Preclinical trials in Solid tumours in USA (IV)